Continuous-flow UVC irradiation: A new, effective, protein activity-preserving system for inactivating bacteria and viruses, including erythrovirus B19

Journal of Virological Methods

Volumn 118, Issue 2, 2004, Pages 131-139

  Caillet Fauquet, Perrine ^a   Giambattista, Mario Di ^c   Draps, Marie Louise ^a   Sandras, Flavienne ^a   Branckaert, Theo ^c   Launoit, Yvan De ^a,b   Laub, Ruth ^c  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSTITUT DE BIOLOGIE DE LILLE   (France)

^c Central Department for Fractionation   (Belgium)

Author keywords

Albumin; Fibrinogen; FVIII; Immunoglobulins; UVC; Viral bacterial inactivation

Indexed keywords

ARTICLE; BACTERIAL STRAIN; BOVINE HERPES VIRUS; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; MICROBIAL ACTIVITY; NONHUMAN; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION DOSE; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION C; VIRUS INACTIVATION; VIRUS STRAIN;

ANIMALS; BACTERIA; BLOOD PROTEINS; BLOOD-BORNE PATHOGENS; CATTLE; DISINFECTION; FACTOR VIII; FIBRINOGEN; HUMANS; IMMUNOGLOBULINS; MICE; PARVOVIRUS B19, HUMAN; PLASMA; ULTRAVIOLET RAYS; VIRUSES;

BACTERIA (MICROORGANISMS); BOVINAE; ENCEPHALOMYOCARDITIS VIRUS; ERYTHROVIRUS; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HERPESVIRIDAE; MICE MINUTE VIRUS; MURINAE; PARVOVIRUS; PICORNAVIRIDAE;

EID: 1842735647     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2004.02.002     Document Type: Article

References (37)

1. Aubin J.T., Defer C., Vidaud M., Maniez Montreuil M., Flan B. Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation. Vox Sang. 78(1):2000;7-12.
2. Aygoren-Pursun E., Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb. Haemost. 78(5):1997;1352-1356.
3. Azzi A., Morfini M., Mannucci P.M. The transfusion-associated transmission of parvovirus B19. Transfus. Med. Rev. 13(3):1999;194-204.
4. Blumel J., Schmidt I., Effenberger W., Seitz H., Willkommen H., Brackmann H.H., Lower J., Eis-Hubinger A.M. Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 42(11):2002a;1473-1481.
5. Blumel J., Schmidt I., Willkommen H., Lower J. Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion. 42(8):2002b;1011-1018.
6. Brown K.E., Young N.S., Alving B.M., Barbosa L.H. Parvovirus B19: implications for transfusion medicine. Summary of a workshop. Transfusion. 41(1):2001;130-135.
7. Chin S., Jin R., Wang X.L., Hamman J., Marx G., Mou X., Andersson I., Lindquist L.O., Horowitz B. Virucidal treatment of blood protein products with UVC radiation. Photochem. Photobiol. 65(3):1997;432-435.
8. Chin S., Williams B., Gottlieb P., Margolis-Nunno H., Ben-Hur E., Hamman J., Jin R., Dubovi E., Horowitz B. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants. Blood. 86(11):1995;4331-4336.
9. Chudy M., Budek I., Keller-Stanislawski B., McCaustland K.A., Neidhold S., Robertson B.H., Nubling C.M., Seitz R., Lower J. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57(2):1999;91-99.
10. de Korte D., Marcelis J.H., Soeterboek A.M. Determination of the degree of bacterial contamination of whole-blood collections using an automated microbe-detection system. Transfusion. 41(6):2001;815-818.
11. Douki T., Cadet J. Individual determination of the yield of the main UV-induced dimeric pyrimidine photoproducts in DNA suggests a high mutagenicity of CC photolesions. Biochemistry. 40(8):2001;2495-2501.
12. Finkel T.H., Torok T.J., Ferguson P.J., Durigon E.L., Zaki S.R., Leung D.Y., Harbeck R.J., Gelfand E.W., Saulsbury F.T., Hollister J.R.et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet. 343(8908):1994;1255-1258.
13. Hart H., Reid K., Hart W. Inactivation of viruses during ultraviolet light treatment of human intravenous immunoglobulin and albumin. Vox Sang. 64(2):1993;82-88.
14. Heegaard E.D., Brown K.E. Human parvovirus B19. Clin. Microbiol. Rev. 15(3):2002;485-505.
15. Hiemstra H., Tersmette M., Vos A.H., Over J., van Berkel M.P., de Bree H. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors. Transfusion. 31(1):1991;32-39.
16. Horowitz B., Wiebe M.E., Lippin A., Vandersande J., Stryker M.H. Inactivation of viruses in labile blood derivatives. II. Physical methods. Transfusion. 25(6):1985;523-527.
17. Koenigbauer U.F., Eastlund T., Day J.W. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion. 40(10):2000;1203-1206.
18. Laub R., Di Giambattista M., Fondu P., Brackmann H.H., Lenk H., Saenko E.L., Felch M., Scandella D. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb. Haemost. 81(1):1999;39-44.
19. Laub R., Strengers P. Parvoviruses and blood products. Pathol. Biol. (Paris). 50(5):2002;339-348.
20. Marx G., Mou X., Freed R., Ben-Hur E., Yang C., Horowitz B. Protecting fibrinogen with rutin during UVC irradiation for viral inactivation. Photochem. Photobiol. 63(4):1996;541-546.
21. McOmish F., Yap P.L., Jordan A., Hart H., Cohen B.J., Simmonds P. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J. Clin. Microbiol. 31(2):1993;323-328.
22. Nakazawa M., Mitjavila M.T., Debili N., Casadevall N., Mayeux P., Rouyer-Fessard P., Dubart A., Romeo P.H., Beuzard Y., Kishi K.et al. KU 812: a pluripotent human cell line with spontaneous erythroid terminal maturation. Blood. 73(7):1989;2003-2013.
23. Pealer L.N., Marfin A.A., Petersen L.R., Lanciotti R.S., Page P.L., Stramer S.L., Stobierski M.G., Signs K., Newman B., Kapoor H., Goodman J.L., Chamberland M.E. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med. 349(13):2003;1236-1245.
24. Prowse C., Ludlam C.A., Yap P.L. Human parvovirus B19 and blood products. Vox Sang. 72(1):1997;1-10.
25. Raut S., Di Giambattista M., Bevan S.A., Hubbard A.R., Barrowcliffe T.W., Laub R. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb. Haemost. 80(4):1998;624-631.
26. Rommelaere J., Vos J.M., Cornelis J.J., Ward D.C. UV-enhanced reactivation of minute-virus-of-mice: stimulation of a late step in the viral life cycle. Photochem. Photobiol. 33(6):1981;845-854.
27. Rommelaere J., Ward D.C. Effect of UV-irradiation on DNA replication of the parvovirus minute-virus-of-mice in mouse fibroblasts. Nucleic Acids Res. 10(8):1982;2577-2596.
28. Saldanha J., Gerlich W., Lelie N., Dawson P., Heermann K., Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 80(1):2001;63-71.
29. Saldanha J., Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufacture. Br. J. Haematol. 93(3):1996;714-719.
30. Shade R.O., Blundell M.C., Cotmore S.F., Tattersall P., Astell C.R. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J. Virol. 58(3):1986;921-936.
31. Sugawara H., Motokawa R., Abe H., Yamaguchi M., Yamada-Ohnishi Y., Hirayama J., Sakata H., Sato S., Kamo N., Ikebuchi K., Ikeda H. Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells. Transfusion. 41(4):2001;456-461.
32. Tattersall P. Replication of the parvovirus MVM. I Dependence of virus multiplication and plaque formation on cell growth. J. Virol. 10(4):1972;586-590.
33. Tattersall P., Ward D.C. Rolling hairpin model for replication of parvovirus and linear chromosomal DNA. Nature. 263(5573):1976;106-109.
34. Thomas I., Di Giambattista M., Gerard C., Mathys E., Hougardy V., Latour B., Branckaert T., Laub R. Prevalence of human erythrovirus B19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins. Vox Sang. 84(4):2003;300-307.
35. van Elsacker-Niele A.M., Kroes A.C. Human parvovirus B19: relevance in internal medicine. Neth. J. Med. 54(6):1999;221-230.
36. Vos J.M., Rommelaere J. Are pyrimidine dimers tolerated during DNA replication of UV-irradiated parvovirus minute-virus-of-mice in mouse fibroblasts? Biochimie. 64(8-9):1982;839-844.
37. Zakrzewska K., Azzi A., De Biasi E., Radossi P., De Santis R., Davoli P.G., Tagariello G. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis. J. Med. Virol. 65(2):2001;402-407.